12 months in and triple agonist is still the thing I get wrong
Long-ish post, sorry. tl;dr at the bottom. I have been tracking retatrutide against triglycerides for 9 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one lab,…
triple agonism is phase 2, do not generalise
That is net peptide content, not purity. Different number, different meaning.
the glucagon component changes the side effect profile, not just the efficacy
What was the dosing schedule in that arm?
Which trial arm and what was the n?
heart rate and dose escalation need actual measurements, not impressions
Dose escalation on retatrutide is steeper and faster than on semaglutide. Do not assume the titration patterns transfer.
The heart rate signal in TRIUMPH is real and concerning. Higher doses had higher mean HR changes.
triple agonism plus glucagon is a different physiological state than GIP/GLP-1 dual
Strongly agree. Heart rate escalation needs the actual data, not impressions.
the glucagon component changes the side effect profile, not just the efficacy